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Associations of triglyceride levels 
with longevity and frailty: A 
Mendelian randomization analysis
Zuyun Liu1,†, Stephen Burgess2, Zhengdong Wang3, Wan Deng1, Xuefeng Chu3, Jian Cai4, 
Yinsheng Zhu3, Jianming Shi3, Xuejuan Xie3, Yong Wang3, Li Jin1 & Xiaofeng Wang1
Observational studies suggest associations of triglyceride levels with longevity and frailty. This study 
aimed to test whether the associations are causal. We used data from the Rugao Longevity and 
Ageing Study, a population-based cohort study performed in Rugao, China. A variant in the APOA5 
gene region (rs662799) was used as the genetic instrument. Mendelian randomization (MR) analyses 
were performed to examine the associations of genetically predicted triglycerides with two ageing 
phenotypes – longevity ( ≥95 years) and frailty (modified Fried frailty phenotype and Rockwood frailty 
index). C allele of rs662799 was robustly associated with higher triglyceride levels in the comparison 
group (β = 0.301 mmol/L per allele, p < 0.001), with an F statistic of 95.3 and R2 = 0.040. However MR 
analysis did not provide strong evidence for an association between genetically predicted triglyceride 
levels and probability of longevity (OR: 0.61; 95% CI: 0.35, 1.07 per 1 mmol/L increase in triglycerides). 
In the ageing arm (70–84 years), genetically predicted triglyceride levels were not associated with the 
frailty index (β = 0.008; 95% CI: −0.013, 0.029) or the frailty phenotype (OR: 1.91; 95% CI: 0.84, 4.37). In 
conclusion, there is currently a lack of sufficient evidence to support causal associations of triglyceride 
levels with longevity and frailty in elderly populations.
Longevity implies exceptional survival and has been considered as a rare but important aging phenotype1. 
Exploiting long-lived individuals (LLIs) (e.g., aged 95+years) as models is well established in human ageing stud-
ies2. On the other hand, frailty signifies a state of increased vulnerability to minor stressor events due to cumula-
tive declines in many pathophysiological systems during ageing and increases in risks of adverse health outcomes, 
such as mortality3,4. To some extent, frailty and longevity represent two complimentary aspects in ageing research 
studies. Investigations into aetiological factors (e.g., blood biomarkers) that contribute to longevity and frailty 
would help to elucidate potential pathophysiological mechanisms of ageing.
Recently, observational studies have suggested associations of triglyceride levels with longevity and frailty5,6. 
However, common limitations such as potential confounding or reverse causation have made it difficult for obser-
vational studies to identify the causal roles of biomarkers in the pathological process of an outcome7. In this 
context, based on the random assignment of genotype from parents that occurs before conception, the Mendelian 
randomization (MR) approach has been proposed to strengthen causal inferences using genetic variants associ-
ated with an exposure (e.g., biomarker) as instrumental variables (e.g., unrelated to potential confounding fac-
tors)7. The principle has been previously applied to triglycerides, which was confirmed as a causal risk factor for 
coronary heart disease (CHD)8. In that study, one variant in the APOA5 gene region (− 1131 T > C, rs662799) was 
used as a proxy of triglyceride concentration8. Indeed, APOA5 rs662799 is in almost complete linkage disequilib-
rium with two other APOA5 polymorphisms: rs2266788 ( +1891 T > C) and rs651821 (− 3 A > G); the haplotype 
constructed by them was found to be associated with approximately 50% lower APOA5 gene expression8. In view 
of the adverse effect of cardiovascular diseases such as CHD on ageing, we examined the causal role of triglyceride 
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level in longevity and frailty using the MR approach. In this study, we aimed to provide evidence for understand-
ing the pathogenesis of ageing and thus potential mechanisms for targeted intervention.
Based on data from the Rugao Longevity and Ageing Study (RuLAS), we used MR analysis to determine 
whether the observational associations of triglyceride levels with the two ageing phenotypes, longevity and frailty, 
are causal. The aforementioned genetic variant rs662799 was used as the genetic instrument.
Results
Table 1 presents the socio-demographic characteristics of LLIs and the comparison group. Relative to compar-
ison group, LLIs were more likely to be illiterate (82.0% vs. 51.2%) and to be regular drinkers (38.5% vs. 29.8%) 
but were less likely to be regular smokers (19.6% vs. 26.6%). The mean values of body mass index (21.5 kg/m2 
vs. 24.1 kg/m2), HDL-C (1.38 mmol/L vs. 1.45 mmol/L), LDL-C (2.51 mmol/L vs. 2.82 mmol/L) and triglyceride 
levels (1.09 mmol/L vs. 1.43 mmol/L) were lower for LLIs.
Analysis of longevity as outcome in case-control design. The APOA5 variant was distributed 
consistently with Hardy–Weinberg equilibrium (p = 0.744) in the comparison group (Table 2). Frequencies of 
variant rs662799 were 70.9% (T allele) and 29.1% (C allele). C allele of rs662799 was robustly associated with 
higher triglyceride levels (beta coefficient (β ) = 0.301 mmol/L per allele, p < 0.001), with an F statistic of 95.3 and 
R2 = 0.040. As shown in Table 3, the APOA5 variant was not associated with the potential confounders listed here.
Each additional copy of the C allele of this variant rs662799 was not strongly associated with probability of 
longevity (Odds ratio (OR): 0.86; 95% confidence interval (CI): 0.73, 1.02, Table 4). MR analysis revealed that 
genetically predicted triglycerides were also not associated with probability of longevity (OR: 0.61; 95% CI: 0.35, 
1.07 per 1 mmol/L increase in triglycerides). The associations above did not change after further adjustments for 
potential confounders and bootstrapping with 1000 replications (Table 4). For comparison, serum triglycerides 
were strongly observationally associated with longevity (OR: 0.52; 95% CI: 0.43, 0.62, p < 0.001). The association 
remained after further adjustments for confounders.
Analysis of frailty as outcome in cross-sectional design. The socio-demographic characteristics of 
the study participants from the ageing arm stratified by APOA5 genotype are shown in Table S1 (Supplementary 
Data). The APOA5 variant was consistent with Hardy–Weinberg equilibrium (p = 0.869). Frequencies of the var-
iant rs662799 in the study sample were 71.9% (T allele) and 28.1% (C allele). The APOA5 variant was not associ-
ated with the potential confounders.
Triglycerides were found to be significantly observationally associated with frailty index (FI) (β = 0.007, 
p = 0.001) based on a cross-sectional design in the ageing arm of the RuLAS; however, a non-significant obser-
vational association was found for the frailty phenotype (OR: 0.99; 95% CI: 0.84, 1.16, p = 0.856). Thus, we used 
standard two-stage regression analysis to test the association of genetically predicted triglycerides on FI in par-
ticipants from the ageing arm. These results are presented in Table 5. Genetically predicted triglycerides were 
not associated with FI (β = 0.008; 95% CI: − 0.013, 0.029, p = 0.440) in an unadjusted model. We also did not 
observe any association of rs662799 with FI (β = 0.003; 95% CI: − 0.004, 0.009, p = 0.442). Further adjustments 
for potential confounders and bootstrapping with 1000 replications did not change the non-significant associa-
tions (Table 5). A MR analysis revealed that genetically predicted triglycerides were also not strongly associated 
with the frailty phenotype (OR: 1.91; 95% CI: 0.84, 4.37, p = 0.124) (Table S2, model 1). The genetic instrument 
No.† Long-lived individuals† Comparison group† P Value‡
Age, years, mean (SD) 2732 97.4 (2.1) 70.6 (5.3) < 0.001
Female, n (%) 2732 343 (78.3) 1430 (62.3) < 0.001
Illiterate, n (%) 2707 346 (82.0) 1170 (51.2) < 0.001
Currently married, n (%) 2707 22 (5.2) 1667 (73.0) < 0.001
Regular smoker (ever), n (%) 2731 86 (19.6) 609 (26.6) 0.002
Regular drinker (ever), n (%) 2713 166 (38.5) 681 (29.8) < 0.001
Body mass index, kg/m2, 
mean (SD) 2725 21.5 (4.2) 24.1 (3.4) < 0.001
Systolic blood pressure, 
mmHg, mean (SD) 2721 136.7 (22.9) 148.1 (25.0) < 0.001
Diastolic blood pressure, 
mmHg, mean (SD) 2731 80.1 (11.0) 82.0 (13.1) < 0.001
Serum lipids, mmol/L, mean (SD)
 Triglyceride 2721 1.09 (0.50) 1.43 (0.97) < 0.001
 HDL-C 2721 1.38 (0.34) 1.45 (0.33) < 0.001
 LDL-C 2721 2.51 (0.70) 2.82 (0.75) < 0.001
Table 1.  Socio-demographic characteristics of long-lived individuals and the comparison group. SD, 
standard deviation; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol. 
†The numbers vary because of missing data in variables. For example, overall 2732 participants include 438 
long-lived individuals and 2294 elderly individuals (comparison group). ‡P values are from the Mann–Whitney 
test for continuous variables or from the chi-squared test for categorical variables, 2-sided.
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rs662799 was not associated with frailty phenotype (OR: 1.20; 95% CI: 0.95, 1.52, p = 0.124) (Table S2, model 1). 
The associations did not change after further adjustments for potential confounders and bootstrapping with 1000 
replications (Table S2).
We also performed sensitivity analysis by combining the elderly group in the longevity arm and elderly par-
ticipants in the ageing arm as controls for longevity. Similar results were observed, including a strong association 
of the rs662799 variant with triglyceride levels and absence of evidence for a causal association of triglycerides 
with longevity.
Discussion
The specific study design in RuLAS provides us with the unique ability to simultaneously examine determinants 
of longevity and ageing9,10. This study used MR analysis to examine the causal associations of triglyceride lev-
els with two ageing phenotypes (longevity and frailty). We observed that the genetic instrument rs662799 was 
robustly associated with triglyceride levels. Moreover, triglyceride levels were also associated with longevity and 
frailty (in particular, FI). However, rs662799 and genetically elevated triglycerides were not associated with the 
probability of longevity nor with frailty. The present results do not support causal associations of triglyceride 
levels with longevity and frailty.
In this study, triglycerides were found to be related to longevity, which is consistent with previous studies 
using long-lived persons11 or their offspring6 as models of longevity. For instance, Vaarhorst et al., observed that 
offspring of nonagenarian siblings from 421 families of the Leiden Longevity Study had lower triglycerides levels 
than their partners6. For frailty, we focused on two of several definitions that have been widely used, including 
the cumulative deficit model and phenotype model3,12–14. In this study, only FI was found to be associated with 
triglyceride levels. With one exception5, no prior study has observed the presence of the association between 
frailty phenotype and triglyceride levels15–18. Note that this only study targeted on 1622 British males aged 71–92 
years without established cardiovascular disease5. The discrepancy between the triglyceride associations with FI 
and frailty phenotype might be attributed to differences in characteristics of the study populations (e.g., ethnics, 
sample size) and the criteria for the definition of frailty. For example, it is reported that FI captures the broader 
spectrum of disorders and could better identify elderly adults at high risk for adverse outcomes than the frailty 
phenotype does in the early stages of frailty3. Discussion on the two frailty measurements is beyond the current 
study but further comparisons and distinctions are needed to elucidate this issue.
Genotype 
or allele No.
P Value 
for HWE
Triglyceride, 
mmol/L, mean 
(SD) β† (SE) P Value
HDL-C, 
mmol/L, 
mean (SD) β† (SE) P Value
LDL-C, 
mmol/L, 
mean (SD) β† (SE) P Value
− 1131T > C 
(rs662799)
TT 1150 (50.1) 0.744 1.29 (0.82) Referent 1.48 (0.33) Referent 2.78 (0.73) Referent
TC 953 (41.5) 1.46 (0.86) 0.169 (0.041) < 0.001 1.44 (0.32) − 0.039 (0.014) 0.007 2.87 (0.77) 0.095 (0.033) 0.004
CC 191 (8.3) 2.09 (1.70) 0.797 (0.074) < 0.001 1.30 (0.31) − 0.177 (0.026) < 0.001 2.78 (0.79) 0.007 (0.058) 0.908
Additive model
T 3253 (70.9)
C 1335 (29.1) 0.301 (0.031) < 0.001 − 0.067 (0.011) < 0.001 0.042 (0.024) 0.083
Table 2.  Associations of the APOA5 polymorphism rs662799 with serum lipids in the comparison group 
(n = 2294). HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol; SE, 
standard error; HWE, Hardy-Weinberg equilibrium. †β refers to the average change in serum lipids (unit: 
mmol/L) with each additional copy of the C allele of this variant rs662799 or using as the “TT” genotype as the 
reference group.
TT TC CC P Value‡
Female, n (%) 897 (64.4) 726 (65.2) 150 (66.7) 0.778
Illiterate, n (%) 780 (56.6) 618 (55.9) 118 (53.2) 0.633
Currently married, n (%) 833 (60.4) 717 (64.8) 139 (62.6) 0.077
Regular smoker (ever), n (%) 363 (26.1) 275 (24.7) 57 (25.3) 0.729
Regular drinker (ever), n (%) 436 (31.6) 344 (31.1) 67 (29.8) 0.863
Body mass index, kg/m2, mean (SD) 23.7 (3.7) 23.7 (3.8) 23.4 (3.4) 0.644
Systolic blood pressure, mmHg, mean (SD) 146.4 (25.4) 146.0 (24.7) 146.4 (24.2) 0.665
Diastolic blood pressure, mmHg, mean (SD) 81.9 (13.5) 81.5 (14.4) 81.6 (10.4) 0.425
Table 3.  Socio-demographic characteristics of long-lived individuals and the comparison group by APOA5 
genotype (n = 2732)†. SD, standard deviation. †The numbers vary because of missing data in variables. Overall 
2732 participants include 438 long-lived indiviudals and 2294 elderly individuals (comparison group). ‡P-values 
are from the Kruskal-Wallis test for continuous variables or from the chi-squared test for categorical variables, 
2-sided.
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Our results suggest that the observational associations of triglyceride levels with longevity and frailty were not 
causal. This result appears to be reasonable when taking into account studies on genetic biomarkers of longev-
ity19–22, FI and frailty phenotype23,24. These findings indicate that the observational associations of triglycerides 
with longevity and FI might involve other factors, e.g., cardiovascular disease. First, triglyceride is synthesized in 
intestinal and liver cells and is subsequently transported through the plasma and acts as a key energy source25. 
Increased triglyceride levels may be related to increased levels of remnant lipoproteins, which may initiate and 
promote the development of atherosclerotic plaques26. These findings could explain the fact that elevated triglyc-
eride levels have been considered as a major independent risk factor for cardiovascular disease8,26,27, a leading 
cause of death in the elderly28–31. Second, it has been proposed that LLIs with extended life span have escaped, 
delayed, or survived major age-related diseases, such as cardiovascular disease32. The above assumption is intrigu-
ing and evidently, requires further scrutiny.
The MR method has some inherent qualifications. For instance, in this study, consistent with other studies33, 
the rs662799 was strongly associated with triglyceride levels in the comparison group but was not associated 
with the potential confounders listed here, indicating that the genetic instrumental variable satisfies the first two 
assumptions in the MR analysis7. Regression analysis in the first stage obtained an F statistic of 95.3 and an R2 of 
0.040 (that is, the genetic variant explains approximately 4% of the between individual variance in triglyceride 
levels) and confirmed that the variant rs662799 could be considered a strong genetic instrument8. In addition, the 
instrument should be related to the outcome (i.e., longevity and frailty) only through its direct effect on modifia-
ble exposure (i.e., triglyceride levels)7,34. Note that a weak association of the variant rs662799 with HDL-C levels 
was observed in this study (β = − 0.067, Table 2). According to previous research, the non-triglyceride-mediated 
pathway would be not excluded and the pleiotropy of rs662799 would be existed. This might be a limitation of 
similar studies, including the current one. However, rs662799 “is a regulatory variant of APOA5 that is predom-
inantly associated with triglyceride concentration”, and the scope for pleiotropy is reduced8. Given the limited 
choice of variants associated with triglyceride concentration, several (unlinked) genetic variants need to be used 
in further studies.
The RuLAS has a unique strength for simultaneously examining factors associated with longevity and frailty – 
two important measurable ageing phenotypes. Participants in the two study arms were from the same city and 
showed a similar genomic background. In addition, the controls were sampled from the original population of 
the case group, which is a pivotal strength for the case-control design because they encounter homogeneous 
environmental exposures.
However, some limitations need to be mentioned. First, the sample size is relatively small (although LLIs in 
this study represent 65.7% of the Rugao LLIs) for MR analysis, potentially leading to biased estimates. Although 
the between individual variance in triglyceride concentrations explained by the genetic variant in our study is 
Model※
rs662799 (Per C allele) MR analysis‡
OR 95% CI P value Causal OR 95% CI P value
1 0.86 0.73, 1.02 0.077 0.61 0.35, 1.07 0.083
2 0.86 0.73, 1.01 0.063 0.59 0.34, 1.04 0.068
3 0.83 0.67, 1.04 0.103 0.55 0.28, 1.12 0.099
4 0.85 0.72, 1.02 0.074 0.59 0.34, 1.05 0.074
Table 4.  MR analysis for the association of triglyceride with longevity based on a case-control design 
(n = 2732)†. MR, Mendelian randomization; OR, odds ratio; CI, confidence interval. †The numbers vary 
because of missing data in variables. Overall 2732 participants include 438 long-lived individuals and 2294 
elderly individuals (comparison group). ※Model 1 unadjusted model; model 2 adjusted for sex; model 3 
additionally adjusted for education level, marital status, smoking and drinking habit, body mass index, systolic 
blood pressure, and diastolic blood pressure; model 4 used bootstrapping with 1000 replications for internal 
validation for model 2. ‡Genetically predicted triglycerides were calculated according to the equation from stage 
1 in the comparison group.
Model※
rs662799 (Per C allele) MR analysis
β‡ 95% CI P Value β‡ 95% CI P Value
1 0.003 − 0.004, 0.009 0.442 0.008 − 0.013, 0.029 0.440
2 0.002 − 0.004, 0.008 0.551 0.006 − 0.014, 0.026 0.550
3 0.003 − 0.004, 0.009 0.426 0.008 − 0.011, 0.027 0.425
4 0.002 − 0.005, 0.008 0.559 0.006 − 0.016, 0.028 0.579
Table 5.  MR analysis for the association of triglyceride with FI based on a cross-sectional design in the 
ageing arm (n = 1750)†. MR, Mendelian randomization; CI, confidence interval; FI, frailty index. †The numbers 
vary because of missing data in variables. ※Model 1 unadjusted model; model 2 adjusted for age and sex; model 
3 additionally adjusted for education level, marital status, smoking and drinking habit, body mass index, systolic 
blood pressure, and diastolic blood pressure; model 4 used bootstrapping with 1000 replications for internal 
validation for model 2. ‡β refers to the average change in FI (no unit) with each additional copy of C allele of this 
variant rs662799 or each unit (mmol/L) increase in genetically predicted triglycerides.
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comparable to those of other similar reports8, we cannot exclude the possibility that the absence of associations 
between genetically predicted triglycerides and longevity and frailty is due to the small sample size. However, we 
observed that no association of the APOA5 gene or the variant rs662799 with longevity or ageing was reported in 
studies using the conventional candidate gene approach19,20 or GWAS21,22. Second, some potential confounding 
factors, such as data on diet were not available, and we cannot adjust for these factors at this moment. However, 
the RuLAS is ongoing, and subsequent re-surveys and follow-ups are anticipatory.
In conclusion, there is currently a lack of sufficient evidence to support causal associations of triglycerides 
with longevity and frailty in the Rugao elderly population. These findings warrant further validation in other 
cohorts with a larger sample size.
Methods
Study design. The study design included two components (Figure S1). First, based on a case-control design, 
we examined the associations of triglyceride levels, rs662799, and genetically predicted triglycerides (MR 
method) with longevity. Second, we tested similar associations for frailty based on a cross-sectional design.
Study population and procedure. All data used in this study were obtained from the RuLAS, a 
population-based observational two-arm cohort study performed in Rugao, a typical medium-sized city of 
Jiangsu province, China. A detailed description was provided in our previous publication9. Briefly, the longev-
ity arm recruited 463 long-lived participants (103 men and 360 women, aged 95 +years of age, range 95–107 
years) between December 2007 and February 2008, representing 65.7% of the Rugao LLIs. Furthermore, 
population-based control groups were randomly recruited from the resident registry at the local government 
offices of Rugao in this arm. The ageing arm of the RuLAS randomly recruited approximately 1960 elderly partici-
pants aged 70‒ 84 years from 31 rural communities of Jiang’an Township, Rugao city, between November 2014 and 
December 2014 according to 5-year age and sex strata. Finally, the sample consisted of a total of 1788 participants 
(91.2%). The current study used data on long-lived participants and the control elderly group in the longevity 
arm and 1750 elderly participants in the ageing arm after data cleaning and a full consideration of study designs.
As previously described9,35, a detailed structured questionnaire and physical examinations (there was a slight 
difference in the two arms) were administered by trained physicians and information such as socio-demographic 
characteristics, lifestyles, past medical history, psychological health, common health deficits (e.g. urinary incon-
tinence), social support/relations, cognitive function, and depression, etc. were gathered9. For parts of older 
adults with cognitive impairment, an appropriate proxy was asked to help accomplish the questionnaire. Written 
informed consent was obtained from each participant or a member of his/her immediate family. The research was 
approved by the Human Ethnics Committee of Fudan University School of Life Sciences and was performed in 
accordance with the approved guidelines.
In this study, the following information was obtained: age, sex, marital status, education level, lifestyles (smok-
ing and drinking habits), body mass index, and blood pressure. Marital status was categorized as currently mar-
ried or other. Education level was categorized as illiterate or literate (≥1 year of education). A participant was 
categorized as a regular smoker (ever) if he/she reported “Yes” to the question, “Have you ever smoked continu-
ously for more than 6 months ? ” or as non-smoker if he/she reported “No.” The same criteria were used to define 
drinking habits. Body mass index was calculated as weight divided by height squared (kg/m2).
Genetic instrument. In East Asians, several SNPs in the APOA5 gene associated with triglycer-
ide levels including rs662799, rs651821 (− 3 A > G), rs3135506 (S19W, c.56 C > G), rs2072560 (715 G > T, 
IVS3 + 476 G > T), rs2266788 (1891 T > C, c.158 C > T, c.1259 T > C), and rs2075291 (c.553 G > T, G185C); 
while four of them (rs662799, rs651821, rs2072560, and rs2266788) were in strong LD36, and the SNP rs662799, 
a regulatory variant in the promoter region of the APOA5, can be the representative of the other three SNPs. 
Additionally, every C allele inherited of the SNP rs662799 was associated with mean triglyceride concentration of 
16%8. Therefore, the variant − 1131 T > C (rs662799) was used as the genetic instrument in this study.
Triglyceride levels. One aliquot of serum was used for clinical testing by a technician in the biochemistry 
laboratory of Rugao Hospital of Traditional Chinese Medicine (in the longevity arm) or Rugao People’s Hospital 
(in the ageing arm). In addition to triglycerides, other blood biomarkers such as high-density-lipoprotein choles-
terol (HDL-C), and low-density-lipoprotein cholesterol (LDL-C) were also examined.
Longevity and frailty. For the case-control design, the long-lived participants were cases of longevity, 
whereas the elderly group in the longevity arm and elderly participants aged 70–79 years in the ageing arm were 
combined as the comparison group.
In the cross-sectional ageing arm, we used two commonly used approaches to operationalise frailty: FI based 
on the cumulative deficit model13,14 and frailty phenotype according to Fried et al.12. A detailed description of FI 
construction was provided in our previous publication10. Briefly, 45 health deficits, including symptoms, activities 
of daily living (basic and instrumental), comorbidity, cognitive and psychological function were used to construct 
a FI according to the standard procedure developed by Searle and Rockwood13,14. Each deficit was dichotomized 
or polychotomized and mapped to the interval 0–1 to represent the severity of the deficit. The FI was calculated 
by summing all deficits and dividing by the total number of deficits (n = 45), with a range from 0 to 1. Continuous 
FI was used in this study.
According to Fried et al.12, five components, including unintentional weight loss, weakness, exhaustion, 
slowness, and low activity were used to define the frailty phenotype. Similar measurements of the five criteria 
were adopted in our study. Detailed descriptions had been provided in our previous publication37. Unintentional 
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weight loss, exhaustion, and low activity were based on self-reports, including “weight has decreased by 4.5 kg or 
5% during the last 12 months,” “feeling tired all of the time (at least 3 or 4 days per a week),” and “needing help 
to walk.” Weakness was based on the self-report of “having difficulty in lifting or carrying something as heavy as 
10 kg,” which was similar to that used in other studies38. Slowness was defined as being below the 20th sex-specific 
percentile in gait speed (assessed through a timed ‘up and go’ test). Participants with three or more of the above 
five components were defined as “frail” or otherwise “non-frail.” Thus, a binary frailty phenotype was used in this 
study.
Statistical analyses. Characteristics were expressed as the mean ± standard deviation (SD) or the percent-
age. The chi-squared was used for comparisons of categorical variables, and either the Mann–Whitney or the 
Kruskal–Wallis test was used for comparisons of continuous variables. A deviation from Hardy–Weinberg equi-
librium for the variant rs662799 was tested using a chi-squared test.
We performed an MR analysis (two-stage regression) to examine the causal association of triglyceride levels 
with longevity. In stage 1, the association of the variant rs662799 with triglyceride levels was analysed using linear 
regression analysis in the comparison group and the β -coefficient was documented. The F-statistic from the linear 
regression analysis of triglycerides on this variant was obtained; F-statistic > 10 suggests that potential bias due 
to weak instruments should not be substantial39. In stage 2, the association of genetically predicted triglycerides 
(calculated according to the equation from stage 1 in the comparison group) with longevity was analysed using 
logistic regression (LLIs vs. the comparison group). Four models were performed in stage 2. Model 1 and Model 2 
were unadjusted and adjusted for sex (age was added for frailty analysis), respectively. Model 3 addition-
ally adjusted for education level, marital status, smoking and drinking habit, body mass index, systolic blood 
pressure, and diastolic blood pressure. Model 4 used bootstrapping with 1000 replications for internal validation 
for model 2.
With respect to frailty, the association of the variant rs662799 with triglyceride levels was analysed using linear 
regression analysis in the ageing arm of RuLAS in stage 1. In stage 2, the association of genetically predicted tri-
glycerides (calculated according to the equation from stage 1 in the ageing arm) with FI was analysed using linear 
regression analysis, whereas the association with frailty phenotype was tested using logistic regression analysis. 
Four models similar to that used in longevity analysis were used in the frailty study.
MR analyses were performed using Stata version 12 (Stata Corp, College Station, Texas, USA). Other analy-
ses were performed using SAS software (version 9.3; SAS Institute, Cary, NC). All P values were two-sided, a P 
value < 0.05 was considered statistically significant except where indicated.
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